Sequential polymerase chain reaction experiments were performed to amplify a unique sequence representing a guanine nucleotide-binding protein (G-protein)-coupled receptor from rat hypothalamic cDNA. Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors
[5-HT1A, 5-HT,c, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions. The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (MR77) containing an intronless open reading frame encoding a 366-amino acid seven-transmembrane domain protein. The human homolog was isolated, and its encoded protein had 93% overall amino acid identity with the rat sequence. Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% amino acid identity with the known rat 5-HT1A, rat 5-HTIB, rat 5-HT1D, and human 5-HT1E receptors, respectively. MR77 was subcloned into a eukaryotic expression vector system and expressed in CosM6 cells. Studies on broken cell preparations indicate that the expressed receptor exhibits 125I-labeled d-lysergic acid diethylamide (LSD) binding that can be displaced by serotonin but not by other biogenic amines. The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed 5-HTIA/1D agonist 5-carboxyamidotryptamine. 125I-labeled LSD binding was competitively antagonized by the ergot alkaloids methysergide and ergotamine. HeLa cells transfected with the MR77 gene exhibited inhibition of adenylate cyclase in response to serotonin. MR77 is expressed at low levels throughout the brain, with the greatest expression in the cortex, hippocampus, and striatum. MR77 thus represents a 5-HT receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HTlE-like receptor.
Serotonin (5-hydroxytryptamine, 5-HT) is a biogenic amine neurotransmitter found in both the central and peripheral nervous systems (for review, see ref. 1) . A majority of serotonin-containing neurons in the central nervous system have cell bodies located in association with the raphe nuclei in the midline area of the brainstem. These cells send projections to the cortex, several limbic structures (hypothalamus, hippocampus, basal ganglia, and amygdala) as well as the lateral geniculate and superior colliculus. Serotonergic transmission through these pathways is thought to be involved with a variety of behaviors and disorders including anxiety, sleep regulation, aggression, and depression. To understand the effects of current drug therapies and also develop additional selective drugs, the receptor systems involved in serotonergic transmission along these pathways must be elucidated.
Pharmacological experiments have suggested that the actions of serotonin are mediated by multiple types of serotonin receptors, each having a distinct profile of activity with respect to serotonin-related drugs (2) . Several serotonin subgroup are characterized by their high affinities for serotonin, whereas 5-HT2 receptors exhibit low affinity. Currently, five 5-HT1 and one 5-HT2 receptor have been identified pharmacologically (5-HT1A, 5-HT1B, 5-HTic, 5-HT1D, 5 -HT1E, and 5-HT2). Genomic and/or cDNA clones for all of these receptors have been isolated, and their sequences have been determined (4) (5) (6) (7) (8) (9) (10) (11) .
In an attempt to identify other receptors that belong to the family of 5-HT receptors, we used a strategy based upon similarities shared among known members of the family. We designed highly degenerate oligonucleotides corresponding to conserved amino acid sequences in putative transmembrane domains III, V, and VI of the 5-HT1A, 5-HT,c, and 5-HT2 receptors. These oligonucleotides were used in sequential polymerase chain reactions (PCR) with rat hypothalamus cDNA as the template to generate a series ofclones. Here we report that one of these clones and its human homolog ¶ correspond to a 5-HT receptor that is more closely related in sequence to the recently cloned human S31 receptor (5-HT1E) than any previously described 5-HT receptor but clearly is a new member of the 5-HT1 receptor family. Initial pharmacological characterization of this receptor, which is negatively coupled to adenylate cyclase, is similar to but distinct from that described previously for the 5-HTlE receptor (9, 12, 13) , and therefore we propose that MR77 belongs to a new subgroup of 5-HTlE-like receptors. Approximately 60 hr after transfection, CosM6 cells were removed from dishes by using EDTA (GIBCO) and a cell scraper and then were collected by centrifugation (250 x g, 5 min). Pellets were resuspended in 50 mM TrisHCl (pH 7.6) with a polytron homogenizer, centrifuged for 20 min at 40,000
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x g, and resuspended in the same buffer (500 ,l1 per 10-cm dish). 125I-LSD (NEN, 2200 Ci/mmol; 1 Ci = 37 GBq) binding was assessed in a 100-,lI final volume and contained 0.02% ascorbate, CosM6 membranes (15 jig of protein), 1 nM 125I-LSD (final concentration), and various unlabeled test compounds. Nonspecific binding was determined by using 100,uM serotonin, and typically was <10% of total dpm.
After 60 min at 37°C, 2 ml of ice-cold 50 mM Tris HCl was added to each tube, and bound ligand was isolated on 0.1% polyethyleneimine-soaked GF/B glass fiber filters, washed twice, and assayed for radioactivity. Protein concentration was measured by the Bradford dye binding method (Bio-Rad) (19) . Binding data were analyzed by nonlinear regression analysis as described (20) .
Cyclic AMP Accumulation. cAMP accumulation was measured by a method similar to that described by Baron and Siegel (21) . HeLa cells were transfected by the calcium phosphate method and utilized 64 hr later. The cells were washed twice with 10 ml of Krebs-Ringer buffer (KRB) containing 134 mM NaCl, 4.7 mM KCI, 2.5 mM CaC12, 2.5 mM MgSO4, 1.18 mM KH2PO4, 11.1 mM glucose, 20 mM Hepes-NaOH, and 0.001% phenol red (pH 7.35). KRB containing 4 ,Ci of [3H]adenine (10 ml per dish) was added, and the dishes were placed in a 37°C air incubator for 2 hr. The dishes were washed once with KRB and once with 10 ml of EDTA, and then the cells were incubated with 10 ml of fresh EDTA for 30 min at 37°C. Cells were resuspended, pooled, and pelleted at 250 x g for 5 min. The final pellet was suspended in KRB containing 0.5 mM isobutylmethylxanthine (IBMX) and 0.02% ascorbate, and 400 ,ul of the cell suspension was dispensed to each assay tube. After a 5-min preincubation at 37°C, the tubes were cooled on ice, various test compounds or KRB/IBMX was added, and the tubes were returned to the 37°C bath for 10 min. The 37°C incubations were ended by placing the tubes on ice and adding 550
IlI of ice-cold 10% perchloric acid containing 5500 dpm of [14C]cAMP, 110 ,ug of unlabeled ATP, 55 ,g of unlabeled cAMP, and 0.002% phenol red. Samples were centrifuged at 3700 rpm for 15 min, and the transferred supernatants were neutralized with 50 ,lI of 10 M KOH. Insoluble KC104 was removed by centrifugation, and 50-i,l aliquots were removed for determination of total radioactivity in each sample. The remaining 1.0 ml was used for determination of cAMP by the sequential Dowex/alumina ion-exchange method (22 Semiquantitative PCR. To determine the tissue distribution of MR77 mRNA expression in rat, we designed a PCR protocol that takes advantage of the intron present in the genomic MR77 clone (Fig. 3A) . Two oligonucleotide primers were designed-one was the inverse complement of nucleotides 590-615, and the other corresponded to the region of the cDNA 20 nucleotides upstream from the putative splice site. In a PCR assay, these primers amplify a 563-bp fragment from cDNA template but not from genomic DNA. Poly(A)+ RNA was isolated from a variety of dissected rat tissues including several brain regions. First-strand cDNA was synthesized from 1 ,ug of poly(A)+ RNA from each tissue by using Moloney murine leukemia virus reverse transcriptase. Two microliters of a 1:10 dilution of each cDNA was used as template in a PCR reaction with the primers described above for 30 amplification cycles; 30 cycles was determined to be within the linear amplification range under the conditions used. Equal aliquots (10 ,l) of each PCR reaction were subjected to agarose gel electrophoresis. The resulting gel was denatured, neutralized, transferred to nitrocellulose membrane, and probed with a radiolabeled oligonucleotide complementary to nucleotides 364-385 of MR77.
RESULTS AND DISCUSSION
Identification of cDNA and Genomic MR77 Clones. We used sequential amplification of rat hypothalamus cDNAs with nested primers and PCR to identify novel 5-HT receptor-like sequences. The first amplification was performed with degenerate primers (with cloning sites) corresponding to portions of the coding regions of putative transmembrane domains III and VI that are conserved among known catecholamine and serotonin receptors from the G-protein-associated receptor superfamily. Products longer than 500 base pairs (bp) were isolated and used as templates in a second amplification designed to amplify cDNAs encoding proteins closely related to known 5-HT receptors (by using the same transmembrane III degenerate primer and a degenerate primer corresponding to residues in transmembrane V that Neurobiology: Lovenberg et al. In addition, the N-terminal putative extracellular domain has two potential sites for asparagine-linked glycosylation at amino acids 5 and 10 ( Fig. 1, black triangles) . There are several potential protein kinase C (circles) and calmodulin kinase II phosphorylation (squares) sites in the large intracellular loop between putative transmembrane domains V and VI (Fig. 1) . These potential posttranslational modifications are similar to those predicted for a variety of G-proteincoupled receptors (24, 25) . MR77 exhibits considerable amino acid homology, particularly within the transmembrane domains, with known 5-HT receptors that are coupled to the inhibition of adenylate cyclase: human S31 (5-HT1E), dog 5-HT1D, rat 5-HT1B, rat 5-HT1A, and rat 5-HTiC with 55%, 48%, 46%, 35%, and 30% overall identity. The primary amino acid sequence of MR77 is most closely related to the recently described human S31 receptor (26) , which has been identified as the 5-HT1E receptor (9) . We screened a human genomic library with rat MR77 and determined the sequence of the human MR77 homolog, which is 86% and 93% identical to rat MR77 at the nucleic acid and amino acid sequence levels, respectively. The human amino acids that differ from those of rat are shown in italics in Fig. 1 . The relationships among the known G-protein-coupled serotonin receptors are graphically illustrated as a dendrogram (Fig. 2) . The Amino acids in italics beneath the rat amino acid sequence represent differences with the human clone.
T P R H A G I T I T T V W V I S V F I S
5-HT1D receptors and the MR77 and 5-HT1E receptors form distinct subfamilies that are more similar to one another than to other receptor types, as determined by amino acid sequence comparisons. In addition, the 5-HT1B, 5-HT1D, MR77, and 5-HT1E receptors are more similar to each other collectively than to 5-HT1A. This may be due in part to the longer putative third intracellular loop in 5-HT1A compared with the other receptors.
Brain Regional Distribution of MR77 mRNA Expression. The tissue distribution of MR77 expression could not be determined by Northern blotting because of the low expression of the mRNA. However, we were able to take advantage of PCR and the fact that the MR77 gene contained an intron in its 5' untranslated region. Primers were designed so as to amplify MR77, producing a 563-bp fragment from cDNA templates but not from genomic DNA (Fig. 3A) . Therefore, detection of amplified product should be diagnostic for the presence of MR77 mRNA. Equal amounts of cDNA made from mRNA extracted from a variety of rat tissues were subjected to PCR, and a major band migrating at approximately 570 bp was observed with some templates (Fig. 3B) . The 570-bp PCR product was subcloned, and its sequence was shown to be identical to the appropriate region of the (Fig. 1) . The distance between oligonucleotides 1 and 2 plus their lengths is 563 bp on the cDNA clone. The distance between point A and B on the genomic clone is not known. (B) The regional distribution of MR77 mRNA expression. cDNAs from the tissues listed were used as templates for the PCR reaction in A. The major band (middle band) migrates at a size approximating 570 bp. The blot was probed with an 32P-labeled oligonucleotide corresponding to nucleotides 257-278 of the genomic clone. Control lanes 12 and 13 contained mRNA templates that had not been reverse-transcribed. MR77 cDNA. The MR77 PCR product was detected in approximately the following abundance: cortex = striatum = hippocampus > thalamus = pons > hypothalamus > cerebellum. This distribution is consistent with known central nervous system terminal fields for serotonergic pathways. The abundance of MR77 mRNA in the cerebral cortex was estimated to be approximately 0.0001% of total mRNA, based on the comparison of the PCR product formed from cortex cDNA template to the product formed from known amounts of cloned MR77 DNA template. No PCR product was detected with liver, kidney, or heart cDNA templates. To show that the PCR products were not the result of amplification of genomic DNA, the same hippocampus and cortex mRNAs used to make cDNA template were additionally used as templates in PCR. These reactions did not yield any products (lanes 12 and 13, Fig. 3B ). Thus, MR77 has a unique pharmacological profile, and its affinity for 5-HT classifies it as a member of the 5-HT, subfamily. The insensitivity of MR77 to 5-CT was similar to that observed for the reported human 5-HTlE receptor (12, 13).
Leonhardt and coworkers (13) demonstrated that the putative 5-HT1E receptor had high affinity for 5-HT, ergotamine, and methysergide but not 5-CT. Although the reported K, values for ligand binding at the 5-HT1E receptor were slightly different than those for MR77, the general trend was similar. McAllister et al. (9) have recently cloned DNA for a human receptor that was identical to the S31 gene and have reported that the pharmacology of the receptor matches exactly that for the putative 5-HT1E receptor (13) . Table 1 lists the K, values for competition binding vs. tritiated 5-HT in cells transfected with the S31 receptor gene. The 5-HT1E receptor is insensitive to sumatriptan, whereas MR77 displays significant affinity for this ligand. In addition, the ergot alkaloids methysergide and ergotamine display lower affinity for the 5-HT1E receptor than for MR77. It should be noted that our binding assays used 125I-LSD, whereas the 5-HT1E studies used tritiated 5-HT. These different agents may result in the variations between affinity constants determined for the ligands tested.
Inhibition of Adenylate Cyclase. The primary structure of MR77 suggested that this receptor may be coupled to the inhibition of adenylate cyclase through an inhibitory G-pro- CONCLUSION The data presented demonstrate that the MR77 gene encodes a 5-HT receptor protein that is expressed predominantly in the central nervous system. The mRNA distribution pattern in the brain is consistent with terminal fields for some serotonergic neurons. MR77 couples to the inhibition of adenylate cyclase and has a binding profile similar to that for the 5-HT1D receptor with the marked exception in affinity for 5-CT. Interestingly, sumatriptan and ergotamine, both of which exhibit high affinity for MR77, have been shown to have clinical efficacy for the treatment of migraine headaches (for review, see ref. 27 ). This raises the possibility that the action of these drugs may be mediated by more than one subtype of 5-HT receptors.
Lately, the identification of receptor genes has outpaced traditional pharmacological identification. Therefore, it has become increasingly difficult to classify receptor gene products on a basis other than amino acid sequence. The pharmacological profile of the MR77 receptor protein is similar to the previously identified 5-HT1E receptor with regard to the apparent insensitivity to the ligand 5-CT but differs with regard to the affinity for sumatriptan. Given that the sequence of MR77 is most similar to 5-HT1E, we propose that the MR77 gene be tentatively identified as another member of the 5-HT1E receptor subgroup.
